 | Up a level |
de Azambuja, E; Agostinetto, E; Procter, M; Eiger, D; Pondé, N; Guillaume, S; Parlier, D; Lambertini, M; Desmet, A; Caballero, C; Aguila, C; Jerusalem, G; Walshe, J M; Frank, E; Bines, J; Loibl, S; Piccart-Gebhart, M; Ewer, M S; Dent, S; Plummer, C; ... (2023). Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial. ESMO open, 8(1), p. 100772. BMJ 10.1016/j.esmoop.2022.100772
Feretti, MT; Merlini, M; Späni, C; Gericke, C; Schweizer, N; Enzmann, Gaby; Engelhardt, Britta; Kulic, L; Suter, T; Nitsch, RM (2016). T-cell brain infiltration and immature antigen-presenting cells in transgenic models of Alzheimer’s disease-like cerebral amyloidosis. Brain, behavior, and immunity, 54, pp. 211-225. Elsevier 10.1016/j.bbi.2016.02.009
Rochlitz, C; Ruhstaller, T; Lerch, S; Spirig, C; Huober, J; Suter, T; Bühlmann, M; Fehr, M; Schönenberger, A; von Moos, R; Winterhalder, R; Rauch, D; Müller, A; Mannhart-Harms, M; Herrmann, R; Cliffe, B; Mayer, M; Zaman, K; Swiss Group for Clinical Cancer Research, (SAKK) (2011). Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Annals of oncology, 22(1), pp. 80-5. Oxford: Oxford University Press 10.1093/annonc/mdq319
Zbinden, S; Bühlmann, M; Aebi, S; Suter, T (2010). Kardiovaskuläre Nebenwirkungen der modernen, medikamentösen Krebstherapie. Schweizerisches Medizin-Forum SMF / Swiss medical forum / Forum médical suisse FMS, pp. 143-147. Basel: EMH Editores Medicorum Helveticorum
Noti, F; Zimmerli, S; Goerre, S; Carrel, T; Suter, T (2009). [Does yoghurt gnaw at cardiac valves?]. Praxis - schweizerische Rundschau für Medizin, 98(10), pp. 547-50. Bern: Huber
